Key Points
- Spyre Therapeutics CFO Scott Burrows sold 7,500 shares on April 1 at an average price of $49.34 for $370,050, reducing his position by 7.11% to 97,994 shares; the transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
- SYRE recently traded near $47.58 (50‑day MA $40.00, 200‑day MA $30.94) with a one‑year range of $10.91–$51.06 and a market cap of about $3.74B; analysts hold an average Buy rating with a consensus target of $60.67, though the company missed last quarter's EPS estimate (‑$0.70 vs. ‑$0.66).
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of Spyre Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $49.34, for a total value of $370,050.00. Following the completion of the sale, the chief financial officer directly owned 97,994 shares in the company, valued at approximately $4,835,023.96. The trade was a 7.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Spyre Therapeutics Stock Performance
NASDAQ SYRE opened at $47.58 on Friday. The stock has a 50 day moving average price of $40.00 and a 200-day moving average price of $30.94. Spyre Therapeutics, Inc. has a one year low of $10.91 and a one year high of $51.06. The company has a market capitalization of $3.74 billion, a P/E ratio of -22.88 and a beta of 2.93.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.04). As a group, equities analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current fiscal year.
Institutional Trading of Spyre Therapeutics
Several institutional investors have recently added to or reduced their stakes in SYRE. Persistent Asset Partners Ltd purchased a new position in shares of Spyre Therapeutics during the fourth quarter valued at approximately $74,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Spyre Therapeutics by 61.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company's stock worth $124,000 after buying an additional 1,435 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Spyre Therapeutics by 2,881.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company's stock worth $71,000 after acquiring an additional 4,092 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Spyre Therapeutics by 182.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company's stock worth $86,000 after acquiring an additional 3,725 shares during the last quarter. Finally, Martingale Asset Management L P purchased a new position in Spyre Therapeutics during the 4th quarter valued at $227,000. Institutional investors own 80.39% of the company's stock.
Analysts Set New Price Targets
SYRE has been the topic of several analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Citigroup began coverage on Spyre Therapeutics in a research note on Wednesday, December 17th. They issued a "buy" rating and a $64.00 price objective for the company. Leerink Partners upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Thursday, February 19th. Wells Fargo & Company increased their price target on Spyre Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Friday, February 20th. Finally, Mizuho upgraded Spyre Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $60.67.
Read Our Latest Stock Report on Spyre Therapeutics
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
